Introduction 1:1 and 2:1 minor groove binding drugs -incomplete specificity
B-DNA minor groove binding drugs, such as the polyamide drugs netropsin and distamycin (Figure 1) , have more potential for recognizing defined base sequences than do intercalators, which insert flat organic rings between base pairs adjacent to them. This is because the intercalators essentially 'see' only the base pairs adjacent to them, whereas the groove-binding drugs can extend for many steps along the floor of the groove. Netropsin, distamycin and other chemically unrelated minor groove binders share four common properties -an overall flat molecule of thickness comparable to that of an organic ring (but twisted at single bonds); a crescent shape that helps it fit along the floor of the groove; hydrogenbond donors along the concave edge of the crescent, available to form bonds with N and O atoms on base edges; and an overall positive charge, complementary with the negative charge of the target DNA. Virtually all of these groove-binding drugs are specific for AT regions of the minor groove, and avoid regions of GC base pairs.
The first X-ray structure of a groove-binding drug in complex with DNA, that of netropsin with C-G-C-G-A-A-T-T-C-G-C-G [1] [2] [3] , showed the basis for this AT-specificity. Firstly, the reading of AT-base pairs is accomplished by means of non-bonded contacts between the C2 hydrogen on adenine and the netropsin pyrrole CH or methylene groups. Secondly, because an AT base pair has only two hydrogen bonds, it can twist or propeller more than a GC pair with three such bonds. Propeller twisting narrows the groove by shifting the positions of C1′ atoms (see Figure 9 of [4] ), producing a narrow groove that is hospitable to a planar drug molecule. Thirdly, the absence of an N2 amine group on adenine makes the groove deeper; conversely, the guanine amine tends to push the drug away. Finally, the electrostatic potential well is deeper in AT regions of the minor groove than in GC regions, probably because of the absence of this same amine group [5] [6] [7] . Hence, a cationic drug is more strongly attracted to AT regions.
Both netropsin and distamycin can be regarded as polypeptide chains in which each alpha carbon has been replaced by a five-membered pyrrole ring. The repeat distance in such an augmented polypeptide chain is almost the same as the distance from one base pair to the next along the floor of a B-DNA minor groove (but not quite; see [8] ). Hence, both the Lown group in Alberta and the Dickerson group at UCLA simultaneously conceived the idea of 'lexitropsins' -longer chain analogues of netropsin which retain pyrrole groups at those positions where an AT base pair was to be read, but substitute imidazole groups at sites where GC base pair reading was desired [1, 9] . Imidazole, it was argued, would both provide room for a guanine amine group and provide an acceptor for a new hydrogen bond (see Figure 5 of [1] ). Initial lexitropsins with positive charges at both ends like netropsin were nonspecific rather than GC-specific; electrostatic attraction appeared to overwhelm purely steric factors [9] [10] [11] [12] . Monocationic lexitropsins based on a parent distamycin proved more promising in recognition of GC regions [13] [14] [15] . But it was still impossible to discriminate between end-for-end reversals (such as AT for TA) of either an AT or a GC base pair. The drug occupies the Molecular structure and nomenclature of netropsin, distamycin and two lexitropsin derivatives. Shorthand designations below names are explained in text. Rings and amide groups are numbered separately from left to right, the conventional -NH-(Py/Im)-CO-'forward' direction of the polypeptide backbone. Note that 2-imidazole netropsin differs from distamycin by substitution of imidazole (q) for pyrrole (l) at ring number 1, and by the absence of a leading amide group (=). All four have a cationic tail (+), but only netropsin also has a cationic head group at its left end.
center of the narrow minor groove, and patterns of minor groove hydrogen-bond donors and acceptors on either base pair also are little changed upon reversal of the pair -AT for TA and GC for CG ( Figure 2 ). At best these minor groove binders had the potential of reading only half the information in the minor groove, and were not even doing that very well.
The field was changed radically when Pelton and Wemmer demonstrated by NMR techniques that, at sufficiently high drug to DNA ratios, two distamycin molecules could sit side-by-side within a widened minor groove [16] [17] [18] [19] . Both AT and GC regions can be used, given the proper drug analogues. GC regions are already almost wide enough for side-by-side binding, and normally narrow AT regions are flexible enough to open to the requisite width. Each drug molecule in a side-by-side complex in effect reads one strand of the DNA duplex. Hence, these side-by-side complexes have now raised the possibility, not only of distinguishing AT from GC base pairs, but of discriminating between end-for-end inversions of a given base pair -AT versus TA and GC versus CG. The full sequence information of the B-DNA duplex may be available for readout through the minor groove.
The geometry of side-by-side binding
Both the original NMR and subsequent X-ray crystallography studies [20, 21] revealed several important principles for side-by-side binding of distamycin and its lexitropsin relatives. These are illustrated in Figure 3 by the di-imidazole lexitropsin bound to C-A-T-G-G-C-C-A-T-G, which is the subject of this paper:
1. Only monocationic drugs can form 2:1 side-by-side complexes, and these molecules are staggered so as to place their cationic tails far from one another. Dicationic netropsin analogues do not form 2:1 complexes, presumably because of charge repulsion between adjacent tails. [57] . Note that hydrogen-bonding positions in the minor groove nearly coincide following base pair reversal, making it intrinsically difficult to detect base pair reversals via minor groove ligands. In contrast, hydrogen-bond donors and acceptors and the thymine methyl in the major groove occupy radically different positions following base pair reversal, permitting easy discrimination of base pair orientation by major groove probes.
2. The -NH-(Py/Im)-CO-... direction from left to right, in each of the drug drawings of Figure 1 , follows the 5′ to 3′ direction of the oligonucleotide chain with which it makes closer contact. That is, the formal 'forward' directions of polypeptide drug and DNA chains happen to be the same.
3. Within the reference frame of the two side-by-side polyamide drugs, stacking of one drug on the other is always ring-upon-amide, never ring-upon-ring. Each polarizable five-membered ring prefers to stack over the polar NH and CO groups of a neighboring amide link.
Figure 3
Stereo views of the complex of the diimidazole lexitropsin, o Im-Im + or = q = q = +, in a 2:1 complex with C-A-T-G-G-C-C-A-T-G. Minor groove filled with two drug molecules below; empty major groove above. (a) DNA is shown in yellow stick bonds, with red bonds for the two guanine nucleosides that are specifically recognized by the drug. Two drug molecules are stacked in opposite directions down the groove, with O shown in red, C in dark blue and N in light blue. Note how the imidazole rings of one drug stack against amide groups of the other drug, not against that drug's imidazoles. This at first surprising finding is in fact quite consistent with the 'polar-on-polarizable' stacking observed in crystals of nucleic acid constituents [22] , hydrophobic interiors of proteins [23, 24] , aromatic molecules in general [25] and oligonucleotides [26] . 4 . Because the minor groove runs at roughly a 40° angle to the DNA helix axis, the ring-upon-amide stacking just mentioned ensures that two drug rings sit next to one another at approximately the level of each base pair. Hence, a given base pair has a five-membered ring from each drug molecule associated with it, although it must be emphasized that these rings are not adjacent to one another in the ring-on-amide stacking of one drug on its neighbor.
The proliferation of distamycin analogues employed in side-by-side drug complexes, and a sometimes not obvious chemical nomenclature, have made it useful to define a chemical shorthand that identifies the drugs and clarifies how they stack against one another, ring against amide, and with bases of the DNA duplex. This shorthand terminology is illustrated below the names of the four drugs in Figure 1 . The simplest representation merely lists pyrrole versus imidazole rings in a forward direction along the polypeptide chain, with + or o to indicate charged or uncharged ends, respectively. A more detailed representation symbolizes the pyrrole ring by an open ring, l, imidazole by a filled ring, q, an amide by a double link, =, and a cationic tail by +. Hence, two-ring di-cationic netropsin is + = l = l = +, three-ring monocationic distamycin is = l = l = l = +, and the di-imidazole lex-
The issue of presence or absence of a leading amide requires a fifth principle, of equal weight to the four listed above: A drug without the leading amide achieves maximum stacking (and acceptable separation of positive charges) in the manner shown below, with the first ring of one drug molecule stacked over the final amide of its neighbor.
This is termed maximum overlap stacking. In contrast, if a leading amide group is present, then the upper drug can slide one step to the right, separating the cationic tails still further, while preserving exactly the same number of ringupon-amide stackings, see below. This is designated as one-residue stagger.
This difference in drug stacking behavior will have drastic implications for any theory of base sequence recognition by side-by-side drugs. Essentially two different 'languages' of sequence recognition apply, depending on whether a leading amide group is present or not.
The above typographic diagrams lend themselves to a convenient shorthand representation of base recognition. Because the minor groove in B-DNA is roughly at 40° to the helix axis, an unrolled-cylinder ladder diagram of the drug complex appears as at left of Figure 4 . This diagram illustrates all five of the principles enumerated earlier: monocationic drugs with widely separated tails, same forward direction for a drug backbone and its nearer DNA strand, ring-upon-amide stacking of neighboring drugs, two adjacent rings at each given base pair level and maximal overlap packing in the absence of a leading amide. The ladder diagram of Figure 4 , although informative, is tedious to construct. But the typographic representation Unrolled-helix representation of drug binding within the minor groove of B-DNA (left), along with a convenient typographic representation (right). l represents a pyrrole ring and q an imidazole or in some cases it represents a pyridine ring in the first position. An -CO-NH-amide is represented as = and + is a positively charged tail. Diagonal lines in typographic representation (right) indicate the plane of base pairs, and the helix axis is normal to these.
of drug packing that we have just seen can be turned into the equivalent of a helix ladder diagram, rotated so the minor groove direction is along the line of type, as at right in Figure 4 where the lexitropsin o Im-Py-Py + , without a leading amide is schematized. Here, the diagonal lines of the typographic representation serve as a reminder of the plane of the base pairs. One base, two associated drug rings and the complementary base lie along a diagonal line from upper left to lower right, as in the second base pair from the left which would be read as G/Im,Py/C.
The code for DNA sequence recognition
Lown, Wemmer and collaborators have studied a series of lexitropsins, such as 2-imidazole-distamycin = l = q = l = + [27, 28] and cross-linked dimers [29] [30] [31] [32] , all with a leading amide. In contrast, Dervan and coworkers at Caltech have synthesized lexitropsins without a leading amide, including 2-ImN ( Figure 1 ) and an analogue, 2-PyN, in which the first ring is a six-membered pyridine instead of five-membered imidazole [33] [34] [35] [36] [37] [38] . Both of these drugs can be represented conveniently by q = l = l = +. (The compounds 2-ImD, 2-ImN and 2-PyN illustrate the confusion in current nomenclature. In one convention, the '2' indicates the position in the drug of the imidazole ring; in the other convention, the '2' describes the C2 attachment to the initial 5-membered ring.) From this work has come a code for reading DNA base pairs by side-by-side drugs [39, 40] : firstly, Im and Py rings side-by-side recognize a GC base pair, with Im specifically selecting the guanine side; secondly, two adjacent Py rings at a given base pair recognize an AT or TA base pair without regard to endfor-end orientation. Experiments by Hartley and coworkers on GC base recognition [15] , as well as this work, suggest yet a third line to the code -two adjacent Im rings recognize a GC or CG base pair without regard to orientation. This augmented code is shown in Table 1 .
The association of pyrrole with AT base pairs and imidazole with GC pairs is sterically understandable, given earlier experience with polyamide lexitropsins in 1:1 drug:DNA complexes [1, 2, 9] . But why should the imidazole of an Im,Py pair necessarily go to the side with guanine? Because the guanine amine sits in the center of the groove, could it not form a hydrogen bond with an imidazole ring positioned to either its left or its right? To help shed light on these questions, we have examined the crystal structure of a monocationic di-imidazole lexitropsin, = q = q = +, with the DNA decamer C-A-T-G-G-C-C-A-T-G, and observed it to bind in the following manner:
Results and discussion

Drug-DNA Interactions
The complex of = q = q = + with C-A-T-G-G-C-C-A-T-G was crystallized and found to be isomorphous with the parent DNA, not in complex with the drug [41] . The crystal structure was solved by molecular replacement, as outlined in Materials and methods. The final refined structure of the 2:1 drug:DNA complex is shown in Figure 3 . The complex obeys all five of the principles enunciated earlier -it is a monocationic polyamide drug, drug and nearer DNA chain run in the same direction, ring-upon-amide stacking occurs between drug molecules, drug rings are paired approximately at base pairs and a one-residue stagger in drug packing occurs because of the presence of a leading amide.
Each drug molecule interacts primarily with one backbone chain of the DNA helix, di-imidazole 1 (DIM1) with bases C 7 A 8 T 9 G 10 on the first strand of helix and DIM2 with bases G 14 G 15 C 16 C 17 on the second strand. NMR analysis of a 1:1 complex between the di-imadazole and the same DNA sequence [42] found the binding region to be C 6 C 7 A 8 T 9 , a one-base shift from the DIM1 site observed by X-ray diffraction. Figure 5 shows a close up of each drug-DNA interaction, with the DIM1 diagram inverted to place it in the same relative orientation as DIM2. All drug-DNA distances of 3.5 Å or less are listed in Table 2 , along with a few longer values needed to maintain the symmetry of DIM1 versus DIM2 binding.
The first observation is that each polyamide makes intimate van der Waals contacts with one wall of the minor groove. As listed in Table 2 and seen in Figure 5 , each sugar O4′ bridges amide and Im nitrogens, in a zig-zag pattern of close contacts. Although these contribute much to the stability of the complex, they make no contribution to its specificity. All of the drug-DNA hydrogen bonds of a 1:1 complex are retained in this 2:1 complex, but divided equally between the two drug molecules. One can think of creating a 2:1 complex by cutting the drug molecule of a 1:1 complex in half lengthwise, pushing each half toward one of the DNA backbone chains ( Figure 6 ) and shifting it a quarter base pair repeat distance towards the 3′ end of its DNA strand. The same bonds are formed with base edge N or O atoms. But now the bifurcated bonds of the 1:1 complex (labeled a-f in Figure 6a ) are replaced by separate sets of bonds from the two drug molecules (a-f in Figure 6b and Table 2 ). Two other hydrogen bonds (g and h) are present from the amine groups on guanines 14 and 15 to the two imidazole rings on DIM2, and it is these bonds that establish the GC versus AT specificity of binding. Two further hydrogen bonds connect the amidinium tails of the drugs to DNA.
Base specificity: AT/TA versus GC/CG
Of the four factors that are invoked to account for ATspecificity in 1:1 groove-binding complexes -van der
Waals contacts, groove depth, groove width and electrostatics -the first two factors remain most relevant for 2:1 complexes. Pyrrole rings favor AT base pairs, because, in making van der Waals contact with the floor of the groove, the extra bulk of the ring C-H demands the empty space provided by the absence of an N2 amine. Conversely, imidazole rings favor GC base pairs because their ring N atom provides both space for the guanine amine and an acceptor for a new hydrogen bond from it [1, 9] . The guanine N2 is the only hydrogen bond donor in the minor groove.
Base specificity: GC versus CG
If the N2 amine nitrogen of guanine truly sits in the center of the minor groove, then why should it not be able Table 1 Sequence recognition in the minor groove by side-by-side polyamide lexitropsins.
Rings side-by-side
Base pair read
Original scheme Im, Py G-C Py, Im C-G Py, Py A-T or T-A Im, Im G-C or C-G Proposed scheme Im, Py G-C Py, Im C-G Th, Py* A-T Py, Th* T-A *Th is thiazole.
Figure 5
Closeup views of single strand recognition by individual lexitropsin molecules. Hydrogen bonds and van der Waals interactions as in Figure 3b . (a) Sequence-specific reading of G 14 G 15 C 16 C 17 by DIM2. Orientation as in Figure 3 . Backbone chain runs from G14 at lower left to A18 at upper right. (b) Nonspecific reading of C 7 A 8 T 9 G 10 by DIM1. View of Figure 3b is inverted to place backbone and drug in comparable orientations to (a). Backbone chain runs from C7 at lower left to G10 at upper right. In both drug molecules, each amide NH is hydrogen bonded (thin red dashed lines) to a N or O on a base edge. Each imidazole N in (a) is hydrogen bonded to a guanine amine (thick red dashed lines) and also packed in close contact against the O4′ of a sugar ring. In (b), imidazole hydrogen bonds are replaced by van der Waals contacts (green dashed lines) and the stacking of drug rings against sugar rings is less orderly. Nitrogen atoms in the drug are colored in blue.
(a) (b)
to bind an Im from either side of the groove? The present DIM-DNA structure was designed to bring two Im rings into contact with the same GC base pair -one hydrogen bonded specifically to the guanine amine, the other interacting nonspecifically with cytosine. Figure 7 suggests that this specificity involves a combination of stereochemistry and bond distances. The closest approach of the two imidazole rings to the GC base pair is controlled by two flanking hydrogen bonds from drug NH groups to ring acceptors -a 2.80 Å N-N separation between the DIM2 NH and guanine N3 (labeled d in Figure 7 ) and a 2.94 Å N-O separation between the DIM1 NH and cytosine O2 (labeled a in Figure 7 ). These bonds position the two drug rings relative to the GC base pair. The guanine amine N2 is delocalized into the aromatic ring system with sp 2 hybridization. The 120° bond geometry of sp 2 hybridization points one hydrogen atom directly at the cytosine O2 to which it is hydrogen bonded and the other hydrogen directly toward the imidazole N of DIM2.
There is no inevitable reason why X-H ... X hydrogen bonds must be linear, because hydrogen bonds contain more of a polar than a covalent character, and indeed many hydrogen bonds exhibit X-H ... X angles of as little as 92° [43] . But distance arguments are more compelling. Because of positioning hydrogen bonds a and d in Figure 7 , the ring nitrogen of DIM1 is held 3.46 Å away from the guanine N atom, whereas the equivalent nitrogen of DIM2 can come to within 3.21 Å of the guanine nitrogen. More to the point, if a 1.0 Å N-H distance is assumed, then the hydrogen atom available for hydrogen bonding is 2.2 Å away from the N of DIM2 and a full 3.2 Å away from N of DIM1. The former distance is somewhat long but not unheard of for a hydrogen bond; the latter is out of range [43] . Hence, an imidazole at the guanine end of the base pair forms a hydrogen bond with the guanine amine, whereas an imidazole on the cytosine end cannot get close enough.
Base specificity: AT versus TA
The recognition code in its present form does not differentiate between the two end-for-end orientations of an AT base pair. Is there any hope of expanding the code to differentiate AT from TA? A look at the minor groove in Figure 2 shows that the pyrimidine O2 atom extends farther into the minor groove than the purine N3 atom. Indeed, this behavior of O2 versus N3 is also visible in Figure 7 ; if the guanine amine is deleted, then the geometry of the purine-pyrimidine pair allows closer approach on the purine side. This suggests that thymine might be repelled systematically by increasing the bulk of the ring in contact with it, causing the bulkier ring to favor adenine. Hence, an expanded recognition code would add:
T/Py,X/A A/X,Py/T where X represents the new and larger ring. The bulk of the contacting five-membered ring could be enhanced by replacing the pyrrole contact CH with CH 2 (as in cyclopentadiene), S (in thiophene or thiazole), C = O (cyclopentanone or cyclopentenone) or methyl, C-CH 3 . It is true that an added methyl group may be too large, and ketones may be too reactive. Chemical synthesis and footprinting analyses will be needed to test this. But Lown and coworkers have already carried out studies using thiazole lexitropsins, which direct a sulfur atom toward the floor of the groove [44] . They report that thiazole lexitropsins 'exhibit strict preference for AT sequences and are even more discriminating than distamycin'. Perhaps a side-by-side pairing of pyrrole with thiazole is a good point of departure for footprinting experiments.
The desired AT versus TA selectivity is demonstrated by the TATA-binding protein or TBP, which discriminates between TA and AT at the first base pair of eight in the TATA box, but not at the eighth base pair [45] . The first position is very influential in determining the suitability of a sequence as a functioning TATA box. Wobbe and Struhl [46] have exhaustively examined point mutations of the TATA sequence, T-A-T-A-A-A, and found that reversal of the first base pair, yielding A-A-T-A-A-A, reduces in vitro activity to 30-33% in both HeLa and yeast cell assays. At the first base pair of the TATA box ( Figure 5 of [45] ). TBP pushes a proline sidechain snugly up against the N3 atom on the adenine side of the base pair. Modeling of reversal of the TA pair indicates that the O2 atom of thymine would exhibit a mild steric clash with proline, disfavoring the reversed orientation. It has been shown recently that TBP-TATA box complexes can be induced to crystallize with the 'wrong' base, T, G or C, at the critical first base pair recognition locus on the second strand (SK Burley, personal communication). The protein simply adjusts slightly to make room. But the question is, at what cost in free energy? A protein is inherently elastic, not rigid. Even a modest free energy difference could produce the kind of selectivity that is observed by Wobbe and
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Figure 7
Structural basis for the ability of imidazole to discriminate between GC and CG base pairs. Imidazole rings from DIM2 (left) and DIM1 (right) are held at fixed distances from the GC base pair. DIM2 can sense the presence of guanine via an hydrogen bond (g) to the N2 amine of guanine 14, one of whose H atoms points directly at the imidazole by virtue of sp 2 hybridization at the amine nitrogen. DIM1, on the other side of the minor groove, is farther from the N2 atom, and is badly oriented relative to the amine hydrogens. Critical N-N distances in Å from Table 2 are g = 3.21, i = 3.46, d = 2.80 and a = 2.94.
Struhl [46] . Substitution of G for the initial T is even more catastrophic. To the injury of pyrimidine at the proline locus then is added the insult of an amine in the center of the groove, and activity falls to 5-8%.
If the foregoing proposal for AT discrimination proves valid in tests now under way, then the complete basereading code can be summarized as:
G/Im,Py/C C/Py,Im/G A/Th,Py/T T/Py,Th/A where Th represents thiazole or one of the other bulky groups described in the previous section. Considering the paired pyrroles of side-by-side distamycins as a starting point, replacement of one pyrrole by thiazole would produce orientation-specific AT recognition, just as replacement of one pyrrole by imidazole produces orientationspecific GC recognition.
The two coding 'languages'
As mentioned earlier, the relative alignment of two sideby-side drugs depends very much on whether or not they possess a leading amide. The only other X-ray crystal structure analyses to date of 2:1 side-by-side complexes involve inosine-cytosine (IC) base pairs, which in this context behave like AT pairs [20, 21] . The complex of distamycin with (I-C) 4 has the structure:
This complex, as does ours, exhibits the one-residue stagger expected for a drug bearing a leading amide group. Yet the sequence recognition trials reported by Dervan and coworkers demand what is termed maximum overlap. Hence, two 'dialects' of the recognition code exist, which are controlled by regulating the overlap of side-by-side drug molecules. The four ring o Im-Im-Py-Py + , for example, would read the base sequence G-G-C-C without a leading amide, but would read x-G-%-C-x (where x is any base and % is a GC base without regard to orientation) if a leading amide is present:
In sum, it is essential to control the relative alignment of two drugs when designing sequence-specific side-by-side agents. One vehicle, of course, is the leading amide group just mentioned. A second positioning agent is bis-linkages or tethers across the two drug molecules, as have been exploited both by Lown [29] [30] [31] [32] and by Dervan [36, 39] . A third and more radical approach is that of synthesizing longer molecules with flexible 'joints', that will fold back into hairpins to bring the correct rings into contact [47] [48] [49] [50] [51] Studies by both the Lown and Dervan groups indicate an increase in binding affinity of up to two orders of magnitude for side-by-side linked drugs using either hairpins or methylene tethers [29, 47, 52] . For hairpins with γ-aminobutyric acid linkers, Walker et al. [53] have proposed a mathematical model for estimating the free energies of binding to various DNA sequences. In another study [54] , they have designed optimal geometries for linkers between two side-by-side polyamides using not only methylenes, but other heteroatoms in the linking chain. A novel hydrogen bond 'zipper' to hold the side-by-side ligands together has also been designed (see Figure 5 of [54] ). The 'zipper' consists of a row of hydrogen bonds between carbonyl oxygens on one drug molecule and hydroxymethyl groups on the rings of the second.
Once the relative positioning of rings in the side-by-side drug pair has been fixed, then the code or an extension of it can be used to read pre-selected DNA sequences.
Although reading at present is not exhaustive, past experience with thiazole rings and analogies with end-for-end recognition of the TATA box suggest a way of expanding the code toward complete discrimination of GC, CG, AT and TA base pairs.
Biological implications
1:1 complexes between DNA and minor groove binding drugs, such as netropsin, distamycin and their lexitropsin derivatives, can distinguish AT base pairs from GC, but not end-for-end base-pair reversals -AT for TA, or GC for CG. Hence, they can read half the information present in the minor groove. But side-by-side binding of two drugs within a widened minor groove offers a potential for greater discrimination, because each drug effectively reads one side of the groove, or one strand of the helix.
The parent compounds, netropsin and distamycin, can be regarded as polyamide or polypeptide chains in which each alpha carbon is replaced by a pyrrole (Py) ring. Lexitropsins are longer chain polyamide analogues in which one or more pyrroles are replaced by imidazoles (Im). Two pyrrole rings side-by-side across the minor groove favor AT or TA base pairs over GC base pairs, because of space constraints placed by the N2 amine group on guanine. An imidazole and a pyrrole packed side-by-side favor a GC base pair, with G on the imidazole side, because of hydrogen bonding from the guanine amine to the imidazole ring nitrogen. Hence, GC can be differentiated from CG by the proper arrangement of imidazole and pyrrole rings.
It is proposed that end-for-end discrimination in AT base pairs might be provided by means of a still bulkier thiazole (Th) ring, which would prefer the A end of an As the ring-plus-amide repeat length along the drug is roughly comparable with the distance from one base pair to another along the floor of the minor groove, extended side-by-side lexitropsins may permit binding selectively and specifically to a pre-chosen DNA sequence. This can be potentially useful to vector a drug for a specific target in chemotherapy, to probe genomic DNA to locate specific sequences, and, with the addition of molecular scissors, becomes a useful tool for gene therapy.
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Figure 8
Difference maps and drug positioning. (a) (F o -F c ) map of DIM1 on strand 1, contoured at 1.2σ. (b) (F o -F c ) map of DIM2 on strand 2, contoured at 1.2σ. These were the first difference maps on which the entire drug molecule -three-ring core and flexible tailwas clearly defined.
Figure 9
Difference maps and drug positioning. DIM/DNA crystals were isomorphous with native CATGGCCATG [41] , crystallizing in space group P2 1 2 1 2 1 with cell dimensions a = 36.654 Å, b = 42.643 Å, c = 34.684 Å, and diffracted to 1.8 Å. The structure was solved by molecular replacement with XPLOR [55] , using as the starting model an ideal CATGGCCATG helix fitted onto the CATGGCCATG coordinates for proper placement in the cell. Data collection and refinement statistics are given in Table 3 .
Rigid body refinement from 8-3 Å was carried out in five stages using five choices of rigid bodies: the entire double helix; each strand singly, ten individual base pair dinucleotides, including phosphates and sugars; twenty individual nucleotides; and sixty uncoupled bases, sugars and phosphates. The starting R factor was 56.5%, dropping to 42.0% after rigid body refinement. NUCLSQ positional and Brefinement [56] followed, with the gradual addition of data to 1.8 Å. 43 solvent molecules were then added to improve the phases, and a difference map indicated drug density next to C 7 A 8 T 9 G 10 . The threering core of DIM1 could be placed unambiguously in the difference map, and the more flexible tail density became clearer after further refinement and difference maps. In a similar manner, the three-ring core of DIM2 on strand 2 near G 14 G 15 C 16 C 17 was positioned in the difference map first, and its tail added to density after refinement. Figures 8a and b show difference map images of both DIM1 and DIM2 at the point where the entire skeleton of each molecule became clear. Because the DIM2 difference density possessed some ambiguity, two positions were refined for a number of cycles -that drawn in Figure 8b , and a model with the drug shifted down the density crescent by half a repeating unit. The choice with the lower R factor was selected for continued refinement. Figures 9a and b depict the final drug images after refinement.
Refinement continued with the addition of solvent and a hydrated calcium ion. Water molecules were positioned where peaks greater than 1σ appeared in (2F o -F c ) maps and where peaks at least 3σ simultaneously appeared in (F o -F c ) difference maps. With DNA (404 atoms), two drug molecules (26 atoms each), 58 water molecules and one hydrated calcium ion, the final 1σ R factor was 20.0%.
Accession numbers
Original F o data and final coordinates have both been deposited in the Nucleic Acid Data Bank (code GDJ054) and the Brookhaven Protein Data Bank ( code 334D) and are available for immediate distribution. 
